JP5925184B2 - Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染と関連した患者状況のｉｎｖｉｔｒｏ迅速判定法 - Google Patents
Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染と関連した患者状況のｉｎｖｉｔｒｏ迅速判定法 Download PDFInfo
- Publication number
- JP5925184B2 JP5925184B2 JP2013500451A JP2013500451A JP5925184B2 JP 5925184 B2 JP5925184 B2 JP 5925184B2 JP 2013500451 A JP2013500451 A JP 2013500451A JP 2013500451 A JP2013500451 A JP 2013500451A JP 5925184 B2 JP5925184 B2 JP 5925184B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- ifn
- ppd
- mycobacterium tuberculosis
- whole blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000008827 tuberculosis Diseases 0.000 title claims description 61
- 238000000338 in vitro Methods 0.000 title claims description 5
- 108010074328 Interferon-gamma Proteins 0.000 claims description 63
- 102100037850 Interferon gamma Human genes 0.000 claims description 62
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 56
- 210000004027 cell Anatomy 0.000 claims description 48
- 210000004369 blood Anatomy 0.000 claims description 41
- 239000008280 blood Substances 0.000 claims description 41
- 239000000427 antigen Substances 0.000 claims description 38
- 102000036639 antigens Human genes 0.000 claims description 38
- 108091007433 antigens Proteins 0.000 claims description 38
- 238000012360 testing method Methods 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 31
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 30
- 208000036981 active tuberculosis Diseases 0.000 claims description 30
- 102000004127 Cytokines Human genes 0.000 claims description 26
- 108090000695 Cytokines Proteins 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 21
- 108010002350 Interleukin-2 Proteins 0.000 claims description 18
- 238000002405 diagnostic procedure Methods 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 17
- 208000032420 Latent Infection Diseases 0.000 claims description 16
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 claims description 15
- 230000000638 stimulation Effects 0.000 claims description 13
- 238000004458 analytical method Methods 0.000 claims description 11
- 230000007423 decrease Effects 0.000 claims description 11
- 229960005486 vaccine Drugs 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 206010065048 Latent tuberculosis Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000000684 flow cytometry Methods 0.000 claims description 6
- 238000002650 immunosuppressive therapy Methods 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 230000000890 antigenic effect Effects 0.000 claims description 5
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000011256 aggressive treatment Methods 0.000 claims description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 238000011284 combination treatment Methods 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 239000013642 negative control Substances 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 238000003745 diagnosis Methods 0.000 claims description 3
- 239000013641 positive control Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 229930191564 Monensin Natural products 0.000 claims description 2
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical group O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 claims description 2
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- 239000003018 immunosuppressive agent Substances 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 230000004073 interleukin-2 production Effects 0.000 claims description 2
- 229960005358 monensin Drugs 0.000 claims description 2
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 229960001005 tuberculin Drugs 0.000 description 4
- 230000004913 activation Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000033353 latent tuberculosis infection Diseases 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- KQNZDYYTLMIZCT-KFKPYADVSA-N (2e,7s,10e,12r,13r,15s)-12,15-dihydroxy-7-methyl-8-oxabicyclo[11.3.0]hexadeca-2,10-dien-9-one Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\C2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KFKPYADVSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010013453 Disseminated tuberculosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 201000006836 Miliary Tuberculosis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 239000013070 direct material Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000003771 laboratory diagnosis Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009670 mycobacterial growth Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000012954 risk control Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/55—IL-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/555—Interferons [IFN]
- G01N2333/57—IFN-gamma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28270110P | 2010-03-19 | 2010-03-19 | |
| US61/282,701 | 2010-03-19 | ||
| EP10157086.9 | 2010-03-19 | ||
| EP10157086 | 2010-03-19 | ||
| PCT/EP2011/054207 WO2011113953A1 (en) | 2010-03-19 | 2011-03-21 | In vitro process for the quick determination of a patient's status relating to infection with mycobacterium tuberculosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522637A JP2013522637A (ja) | 2013-06-13 |
| JP5925184B2 true JP5925184B2 (ja) | 2016-05-25 |
Family
ID=42457988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013500451A Expired - Fee Related JP5925184B2 (ja) | 2010-03-19 | 2011-03-21 | Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染と関連した患者状況のｉｎｖｉｔｒｏ迅速判定法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20130122523A1 (es) |
| EP (1) | EP2548019A1 (es) |
| JP (1) | JP5925184B2 (es) |
| KR (1) | KR20130029063A (es) |
| AU (1) | AU2011228996B2 (es) |
| BR (1) | BR112012023678A2 (es) |
| CA (1) | CA2793151C (es) |
| CL (1) | CL2012002542A1 (es) |
| CO (1) | CO6640286A2 (es) |
| CU (1) | CU20120141A7 (es) |
| MD (1) | MD20120084A2 (es) |
| MX (1) | MX2012010720A (es) |
| RU (1) | RU2012144417A (es) |
| SG (1) | SG184103A1 (es) |
| WO (1) | WO2011113953A1 (es) |
| ZA (1) | ZA201206950B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9146236B2 (en) | 2010-12-23 | 2015-09-29 | Giuseppe Pantaleo | Methods for differentiating between disease states |
| WO2012167307A1 (en) * | 2011-06-06 | 2012-12-13 | The University Of Melbourne | Diagnosis of mycobacterial infection |
| WO2013106338A1 (en) | 2012-01-12 | 2013-07-18 | Mayo Foundation For Medical Education And Research | Detecting latent tuberculosis infections |
| US10401360B2 (en) | 2013-04-29 | 2019-09-03 | Mayo Foundation For Medical Education And Research | Flow cytometry assay methods |
| GB201315748D0 (en) | 2013-09-04 | 2013-10-16 | Imp Innovations Ltd | Biological methods and materials for use therein |
| US9549914B2 (en) | 2014-04-03 | 2017-01-24 | The Johns Hopkins University | Treatment of human cytomegalovirus by modulating Wnt |
| JP6306124B2 (ja) * | 2016-11-01 | 2018-04-04 | 国立大学法人高知大学 | 結核検査用バイオマーカー |
| EP3555630B1 (en) | 2016-12-14 | 2023-05-31 | Becton, Dickinson and Company | Methods and compositions for obtaining a tuberculosis assessment in a subject |
| CN107831316A (zh) * | 2017-10-31 | 2018-03-23 | 扬州大学 | 一种用于诊断牛结核病的流式细胞术检测试剂盒 |
| CN109777852A (zh) * | 2019-01-29 | 2019-05-21 | 浙江省人民医院 | 特异性抗原刺激cd4淋巴细胞表达cd69用于诊断结核杆菌感染的方法 |
| KR102326294B1 (ko) * | 2019-10-27 | 2021-11-16 | 바디텍메드(주) | 결핵 진단 장치 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7514232B2 (en) | 1996-12-06 | 2009-04-07 | Becton, Dickinson And Company | Method for detecting T cell response to specific antigens in whole blood |
| US7135280B2 (en) * | 2001-01-08 | 2006-11-14 | Isis Innovation Limited | Assay to determine efficacy of treatment for mycobacterial infection |
| WO2006069460A2 (de) * | 2004-12-30 | 2006-07-06 | Medmix Systems Ag | Mehrkomponenten-austragvorrichtung für flüssige und pulverförmige stoffe |
| NZ560468A (en) * | 2005-01-05 | 2010-05-28 | Isis Innovation | Compositions for immunizing against mycobacterium using Ag85A |
| EP1767937A1 (en) * | 2005-09-27 | 2007-03-28 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method of diagnosis of tuberculosis related immune restoration syndrome (IRS) |
| GB0605474D0 (en) * | 2006-03-17 | 2006-04-26 | Isis Innovation | Clinical correlates |
| ES2558543T3 (es) | 2007-03-16 | 2016-02-05 | Cellestis Limited | Un ensayo de respuesta inmunitaria mediada por células y kits para el mismo |
-
2011
- 2011-03-21 EP EP11709133A patent/EP2548019A1/en not_active Withdrawn
- 2011-03-21 MX MX2012010720A patent/MX2012010720A/es not_active Application Discontinuation
- 2011-03-21 US US13/635,348 patent/US20130122523A1/en not_active Abandoned
- 2011-03-21 BR BR112012023678A patent/BR112012023678A2/pt not_active IP Right Cessation
- 2011-03-21 CA CA2793151A patent/CA2793151C/en not_active Expired - Fee Related
- 2011-03-21 SG SG2012068714A patent/SG184103A1/en unknown
- 2011-03-21 JP JP2013500451A patent/JP5925184B2/ja not_active Expired - Fee Related
- 2011-03-21 KR KR1020127027112A patent/KR20130029063A/ko not_active Application Discontinuation
- 2011-03-21 AU AU2011228996A patent/AU2011228996B2/en not_active Ceased
- 2011-03-21 RU RU2012144417/15A patent/RU2012144417A/ru not_active Application Discontinuation
- 2011-03-21 WO PCT/EP2011/054207 patent/WO2011113953A1/en active Application Filing
- 2011-03-21 MD MDA20120084A patent/MD20120084A2/ro not_active Application Discontinuation
-
2012
- 2012-09-13 CL CL2012002542A patent/CL2012002542A1/es unknown
- 2012-09-17 ZA ZA2012/06950A patent/ZA201206950B/en unknown
- 2012-09-19 CO CO12162307A patent/CO6640286A2/es unknown
- 2012-09-19 CU CU2012000141A patent/CU20120141A7/es unknown
-
2014
- 2014-07-07 US US14/324,272 patent/US9476877B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130029063A (ko) | 2013-03-21 |
| US20150099652A1 (en) | 2015-04-09 |
| MD20120084A2 (ro) | 2013-04-30 |
| BR112012023678A2 (pt) | 2016-08-23 |
| US20130122523A1 (en) | 2013-05-16 |
| ZA201206950B (en) | 2013-05-29 |
| AU2011228996B2 (en) | 2015-01-29 |
| SG184103A1 (en) | 2012-10-30 |
| MX2012010720A (es) | 2013-01-29 |
| CL2012002542A1 (es) | 2013-02-08 |
| AU2011228996A1 (en) | 2012-10-11 |
| CA2793151A1 (en) | 2011-09-22 |
| CA2793151C (en) | 2018-05-22 |
| JP2013522637A (ja) | 2013-06-13 |
| EP2548019A1 (en) | 2013-01-23 |
| CO6640286A2 (es) | 2013-03-22 |
| WO2011113953A1 (en) | 2011-09-22 |
| RU2012144417A (ru) | 2014-04-27 |
| CU20120141A7 (es) | 2013-01-30 |
| US9476877B2 (en) | 2016-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5925184B2 (ja) | Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染と関連した患者状況のｉｎｖｉｔｒｏ迅速判定法 | |
| US9146236B2 (en) | Methods for differentiating between disease states | |
| Ault et al. | Altered monocyte phenotypes but not impaired peripheral T cell immunity may explain susceptibility of the elderly to develop tuberculosis | |
| EP1520174B1 (en) | Diagnostic method for determination of M. tuberculosis | |
| Gallant et al. | Impact of age and sex on mycobacterial immunity in an area of high tuberculosis incidence | |
| US20190391148A1 (en) | Flow cytometry assay methods | |
| JP5258584B2 (ja) | 臨床的相関 | |
| Elnaggar et al. | Development of an improved ESAT-6 and CFP-10 peptide-based cytokine flow cytometric assay for bovine tuberculosis | |
| JP2010503846A (ja) | 個体が活動性マイコバクテリア症に進行しやすいかを診断するための方法およびキット | |
| US20150153361A1 (en) | Status of Tuberculosis Infection in an Individual | |
| CA2878497C (en) | Status of tuberculosis infection in an individual | |
| CN109991417A (zh) | 一种结核病的免疫标志物及应用 | |
| Xia et al. | Development of a flow cytometry assay for bovine interleukin-2 and its preliminary application in bovine tuberculosis detection | |
| WO2014140833A2 (en) | Methods for differentiating between disease states | |
| US9678071B2 (en) | Detecting latent tuberculosis infections | |
| RU2576833C1 (ru) | Способ диагностики туберкулеза и дифференциальной диагностики туберкулеза и латентной туберкулезной инфекции | |
| Sarkar et al. | Granzyme B as a diagnostic marker of tuberculosis in patients with and without HIV coinfection | |
| WO2023281263A1 (en) | Diagnosis of latent tuberculosis | |
| WO2022103351A1 (en) | Laboratory and clinical test method for the follow-up of t cell response in the diagnosis and monitoring of covid 19 disease | |
| CN112858688A (zh) | Slamf7表达的cd4+t细胞在制备结核病诊断或治疗试剂中的应用 | |
| Pumpradit et al. | Mycobacterium avium and Burkholderia pseudomallei (Melioidosis) coinfection in an HIV-positive patient | |
| Buldeo et al. | Clinical Study Pulmonary Immune-Compartment-Specific Interferon Gamma Responses in HIV-Infected Individuals with Active Tuberculosis (TB) in an Area of High TB Prevalence | |
| Tena-Coki | Investigations of mycobacteria-specific memoryy/effector T cell responses in HIV infected children receiving antiretroviral therapy | |
| WO2014142646A1 (en) | Q-fever diagnostic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140122 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20140807 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140819 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150218 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150616 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150616 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150721 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151008 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160329 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160419 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5925184 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |